Case 6: Abdominal Distress in a Foal

2018 ◽  
pp. 179-180
Keyword(s):  
The Lancet ◽  
1972 ◽  
Vol 300 (7788) ◽  
pp. 1198-1199 ◽  
Author(s):  
RoyS. Rogers

2021 ◽  
Vol 14 (5) ◽  
pp. e241869
Author(s):  
Merete Berthu Damkjaer ◽  
Waqas Farooqui ◽  
Inge Ifaoui ◽  
Luit Penninga

Sigmoid volvulus in paediatric patients is a rare but potentially life-threatening condition. Since 1940, only 100 cases have been reported. There are no consensual guidelines for juvenile sigmoid volvulus unlike in adults, where the condition and the treatment is well described. We report a case of a 12-year-old patient, who presented with uncharacteristic symptoms of mild abdominal discomfort and lack of passage of stool. A CT-scan showed a sigmoid volvulus and emergency resection was performed with placement of a colostomy. With this case, we want to emphasise juvenile sigmoid volvulus as a probable differential diagnosis when symptoms of abdominal distress and constipation occur.


1990 ◽  
Vol 22 (4) ◽  
pp. 241-243 ◽  
Author(s):  
S. G. KAMERLING ◽  
JENA G. HAMRA ◽  
CLEO A. BAGWELL
Keyword(s):  

PEDIATRICS ◽  
1970 ◽  
Vol 46 (6) ◽  
pp. 973-973
Author(s):  
Tuomas Peltonen

Stone and Barbero made a careful study of a number of children with abdominal distress and arrived at the diagnosis of irritable bowel syndrome. However, a more comprehensive entity was probably involved. Abdominal symptom is only one of many symptoms encountered in this syndrome. As the authors also stated there is headache, pallor, syncope, vertigo, and poor appetite. Certain circulatory symptoms also belong to this same syndrome. I described them in 1956.1 I see this syndrome as an entity which can be entered under the heading of neurovegetative dystonia.


1984 ◽  
Vol 26 (3) ◽  
pp. 147-151 ◽  
Author(s):  
Naftale Katz ◽  
Roberto S. Rocha ◽  
Adelú Chaves

Seventy three children (6-15 years) and 75 adults (18-47 years) with active schistosomiasis mansoni were treated with oltipraz. All cases had at least 100 eggs per gram of feces as determined by the Kato-Katz technique. Children and adults were divided in two groups receiving respectively 25 or 30 mg/kg, as a single oral dose. Clinical examination, laboratories tests (haemogram, urinalysis, hepatic and kidney functions tests, glycemia, cholesterol, triglicerides, lipoprotein — HLD and LDL) and ECG were performed before, 3 or 7 days and 1 month after treatment. Parasitological control with 3 daily coprological examinations, was done on the 1st, 3rd j 6th month after drug administration. Giddiness, somnolence, headache, nausea, vomiting and abdominal distress were the most frequent side effects. Pain in the finger tips that need further investigations also occurred. No significant alteration in complementary tests were observed, whereas eosinophilia 1 month after treatment was detected, probably indicating worm death. The cure rate in children was 81.8% and 74.2% with 25 and 30 mg/kg respectively, and in adults 75.0% and 81.2% of the patients. No statistical significant difference was observed between cure rate and side effects at different dosages employed, neither between adults nor children. In all groups the percentage of egg reduction in feces in the non cured patients was higher than 96.0%. Further investigation with this new compound is necessary to accomplish the real value of oltipraz in the schistosomiasis chemotherapy.


1979 ◽  
Vol 122 (1) ◽  
pp. 83-86
Author(s):  
John P. Donohue ◽  
Robert A. Garrett ◽  
Theodore F. Holland ◽  
Kathleen Warfel
Keyword(s):  

2021 ◽  
Author(s):  
Rapson Gomez ◽  
Deon Tullett-Prado ◽  
Shaun Watson ◽  
Vasileios Stavropoulos

Abstract Background The Covid-19 Pandemic and subsequent actions taken by national/international organizations has generated a large amount of anxiety which may roam into the realm of pathology – COVID Anxiety. In order to measure this phenomenon, measures such as the CAS have been developed. The CAS being a self-report measure of anxiety-related physiologically symptoms that are aroused by information and thoughts related to COVID-19. However, as the CAS is fairly new tit requires validation and examination. This study fulfils this need through the use of Network Analysis. Methods The study used regularized partial correlation network analysis (EBICglasso) to examine the network structure of ratings of COVID anxiety symptoms as presented in the Coronavirus Anxiety Scale (CAS) and how these symptoms are related to distress (combination of depression, anxiety, stress) and alcohol use. A total of 968 adults from an Australian community sample completed the CAS, and measures of depression, anxiety, stress and alcohol use. Results The findings showed that the most central CAS symptom was abdominal distress, followed by tonic immobility. The symptom with the lowest strength centrality value was dizziness. Also, the network revealed at least moderate effect size connections for tonic immobility with dizziness, sleep disturbances abdominal distress, and for abdominal distress with appetite loss. Additionally, distress was associated positively with dizziness, tonic immobility and appetitive loss. Alcohol use was associated positively with dizziness and abdominal distress, and negatively with tonic immobility and appetitive loss. Conclusions Overall, the findings showed a novel understanding of the structure of the COVID anxiety symptoms in the CAS, and how these symptoms are associated with distress and alcohol use. The clinical implications of the findings for assessment and treatment of COVID anxiety and its comorbidity with distress and alcohol use are discussed.


Sign in / Sign up

Export Citation Format

Share Document